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The First Simultaneous Pancreas, Renal 
Transplant in a Patient with HIV in Australia
Abstract
We	report	 the	first	 case	of	a	 simultaneous	pancreas	and	 renal	 transplantation,	
in	Australia,	 in	a	45	year	old	male	with	long	standing	human	immunodeficiency	
virus	 infection,	 type	 1	 diabetes	 mellitus	 and	 diabetic	 nephropathy	 requiring	
haemodialysis.	This	patient	experienced	previous	virological	failure	and	subsequent	
resistance	to	most	nucleoside	and	non-nucleoside	reverse	transcriptase	 inhibitors.	
However,	using	novel	combinations	of	anti-retroviral	agents,	along	with	careful	
monitoring,	 successful	 outcomes	 were	 achieved	 during	 the	 peri	 and	 post	
transplantation	period,	with	excellent	pancreas	and	renal	graft	function	at	one	year.		
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Introduction
Recent	 experiences	 suggest	 that	 transplantation	 can	 be	 safely	
conducted	 in	 patients	 with	 human	 immunodeficiency	 virus	
(HIV)	infection.	Balancing	medication	interactions	between	anti-
retroviral	 therapy	 and	 immunosuppressive	 therapy	 remains	 a	
challenge.	Eight	cases	of	simultaneous	pancreas	and	kidney	(SPK)	
transplantation	 in	 HIV	 patients	 with	 type	 1	 diabetes	 mellitus	
(T1DM)	 have	 been	 reported	 with	 good	 outcomes	 [1-5].	 At	
transplantation,	all	patients	were	under	the	age	of	50	years,	with	
undetectable	 HIV	 RNA	 blood	 levels.	Most	 were	 on	 nucleoside	
reverse	 transcriptase	 inhibitor	 (NRTI)	 based	 regimes.	 Here	 we	
report	the	first	SPK	transplantation	case	in	Australia.	We	highlight	
that	successful	transplantation	can	be	achieved	in	the	context	of	
viral	resistance,	with	the	use	of	novel	anti-retroviral	medications.	
Case
A	 45	 year	 old	 male	 with	 HIV-1	 infection	 was	 referred	 to	 our	
facility	 from	 a	 regional	 area,	 for	 SPK	 transplantation.	 T1DM	
was	 diagnosed	 aged	 19	 years,	 complicated	 by	 nephropathy	
requiring	home	haemodialysis	 in	 the	 three	years	 leading	up	 to	
transplantation.	HIV	was	diagnosed,	aged	24	years.	Eight	years	
later,	lamivudine/zidovudine	and	efavirenz	was	commenced	at	a	
nadir	CD4	count	of	160	cells/mL.	History	was	notable	for	coronary	
artery	bypass	grafting,	previous	seizures	and	fractured	humerus.	
Over	 twenty	 years,	 modifications	 to	 his	 anti-retroviral	 regime	
were	necessary	because	of	adverse	effects	and	virological	failure	
(Table 1).	In	2011,	mutations	at	positions	M184V,	K103N,	M41L	
and	T215CF	were	found,	precluding	the	use	of	most	NRTIs.	In	2014,	
despite	good	virological	control,	anti-retroviral	medications	were	
modified	in	preparation	for	transplantation.	Protease	inhibitors	
(PI)	and	etravirine	were	avoided	due	to	cytochrome	P450	inhibition.	
Instead,	a	novel	combination	including	subcutaneous	enfuviritide	
was	used,	along	with	dolutegravir,	maraviroc	(CCR5	tropic	virus)	
and	renal-adjusted	tenofovir	disoproxil	fumarate	(TDF).
	 Twelve	 months	 later,	 at	 the	 time	 of	 transplantation,	 CD4	
count	 was	 518	 cells/mL,	 HIV	 viral	 load	 was	 undetectable	 and	
CMV	and	EBV	 IgG	were	negative.	 The	donor-recipient	was	0/6	
mismatched	 on	 HLA	 loci.	 Standard	 induction	 therapy	 included	
basiliximab,	 mycophenolate	 and	 prednisone.	 Maintenance	
immunosuppression	was	continued	with	mycophenolate,	renally	
adjusted	tacrolimus,	a	calcineurin	inhibitor	(CI)	and	prednisone.	
Valganciclovir	prophylaxis	was	added.	
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Therapeutic	drug	monitoring	 (TDM)	allowed	gradual	escalation	
of	 the	 CI	 dose,	 with	 the	 aim	 to	 achieve	 adequate,	 yet	 safe,	
immunosuppression	 to	 optimise	 graft	 survival.	 Renal	 function	
fully	recovered	over	three	weeks,	allowing	gradual	escalation	to	
standard	doses	of	TDF	(Figure 1).
Insulin	 was	 no	 longer	 required	 post	 operatively.	 At	 discharge,	
proton	pump	inhibitor	was	ceased	and	enfuviritide	was	changed	
to	rilpivirine	(absorbed	in	acidic	environments).	TDF	was	replaced	
by	 Tenofovir	 alafenamide	 combined	with	 emtricitabine,	 a	 new	
agent	with	reduced	nephrotoxicity.	His	general	health	improved,	
despite	 several	 admissions	with	 psoas	 collection	 and	 a	 splenic	
infarct.	 His	 12-month	 biopsy	 showed	 no	 evidence	 of	 acute	
rejection,	with	a	BANFF	score	of	0	(t0,	 i0,	g0,	cg0,	ah0,	v0,	vv0,	
ct0,	mm0).	However,	there	were	signs	of	early	glomerulopathy.	
HIV	viral	load	remained	undetectable.
Discussion
The	 current	 case	 demonstrates	 that	 the	 presence	 of	 complex	
antiretroviral	drug	resistance	patterns,	requiring	thoughtful	anti-
retroviral	 treatment	 regimens,	 can	 be	 managed	 successfully	
to	 allow	 organ	 transplantation	 in	HIV	 patients.	 The	 favourable	
outcome	here	was	consistent	with	the	other	case	reports	(Table 
2).	Only	one	patient	has	been	reported	as	having	died,	after	SPK	
transplantation,	resulting	from	bacterial sepsis	at	nine	months	[1].	
Graft	failure	has	been	reported	in	two	cases	[1,2].	The	remaining	
five	organ	grafts	have	functioned	at	follow	up	between	5	and	84	
months	[2-5].
Despite	 recommendations	 [6]	 against	 anti-retroviral	 treatment	
interruptions,	 the	 peri	 and	 post-operative	 approaches	 to	 anti-
retroviral	 therapy	 in	 SPK	 transplantation	 have	 varied.	 In	 one	
case,	anti-retrovirals	were	withheld,	without	virological	 failure,	
pre-operatively	and	seven	years	post	 [4].	 In	a	case	series,	anti-
retrovirals	 were	 withheld	 in	 the	 pre	 and	 peri-transplantation	
period	 to	avoid	medication	 interactions.	Reintroduction	was	at	
25-58	days,	with	CD4	counts	71-195	[2].	Our	recipient	and	two	
other	cases	received	uninterrupted	anti-retroviral	treatment	[3,5].
The	 challenges	 faced	 in	 managing	 such	 patients	 are	 diverse.	
The	 primary	 challenge	 is	 that	 drug-drug	 interactions	 need	 to	
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Figure 1 Biochemical	markers	and	tenofovir	dosing	over	time.
Table 1 Anti-retroviral	regimes	over	time.
 June 2002-December 
2004
January 2005-
July 2004
July 2005 January 2011
May 2011-July 
2014
July 2014- 
Transplant
Current
NRTI
Lamivudine/
Zidovudine
Lamivudine/
Abacavir
Lamivudine/
Zidovudine/Abacavir/
Tenofovir
Lamivudine/
Abacavir
-
Tenofovir	
disoproxil
Tenofovir	
alafenamide/
Emtricitabine
NNRTI Efavirenz Efavirenz - - Etravarine - Rilpivirine
Protease 
inhibitor
- - Lopinavir/Ritonavir
Lopinavir/	
Atazanavir/	
Ritonavir
Darunavir/
Ritonavir
- -
Integrase 
inhibitor
- - - - Raltegravir Dolutegravir Dolutegravir
CCR5 
inhibitor
- - - - - Maraviroc Maraviroc
Fusion 
inhibitor
- - - - - Enfuviritide	 -
Reason for 
change
Adverse	effect	
(anaemia)
Viral	failure
Patient	choice	
(treatment	
interruption)
Side	effects	
(hypotension)
Avoid	potential	
drug	interactions
Side	effects	
(injection	site	
reactions)
-
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be	 considered.	 PIs	 inhibit	 the	 metabolism	 of	 CI,	 necessitating	
lower	 doses	 of	 CIs	 [6].	 Conversely	 non-nucleoside	 reverse	
transcriptase	 inhibitors	 (NNRTI)	 can	 increase	 CI	 metabolism,	
necessitating	higher	doses	of	CIs	[6].	Despite	prior	PI	and	NNRTI	
use,	our	recipient	was	prescribed	TDF	(a	NRTI),	regardless	of	risk	
of	nephrotoxicity,	 as	 it	 has	minimal	 interactions	with	 immune-
suppressive	 drugs	 [6,7]	 and	 has	 antiviral	 activity	 despite	 his	
resistance	profile.	
The	 other	 agents	 used:	 integrase	 inhibitors	 (dolutegravir),	
maraviroc	 and	 enfuviritide	 exhibit	 minimal	 interactions	 with	
immunosuppressive	 regimes	 [6-8].	Enfuviritide,	 is	administered	
by	subcutaneous	injection,	limiting	long-term	use.	However,	once	
successfully	 transplanted	 an	 alternate	 regime	 was	 established	
safely.
Other	 challenges	 in	 managing	 patients	 requiring	 SPK	
transplantation	 include	 infective	 complications.	 The	 commonly	
reported	 infective	 complications	 included	 abscesses	 [1,2],	
urinary	tract	infections	[2,4],	CMV	viraemia	[1],	wound	infection,	
bacteraemia	 and	 pneumonia	 [4].	 Interestingly,	 one	 case	 was	
complicated	 by	 a	 psoas	 abscess,	 with	 good	 recovery,	 similar	
to	 our	 recipient	 [2].	 Other	 reported	 long	 term	 complications,	
included	 bleeding	 [2],	 haematoma	 [2],	 cholecystitis	 [2],	 mild	
graft	 rejection	 [5]	 and	 minor	 myocardial	 events	 [4].	 Our	 case	
also	experienced	a	myocardial	event	and	splenic	infarct	but	has	
recovered	subsequently.
The	ethical	implications	of	transplantation	in	potential	candidates	
with	 HIV	 must	 be	 considered.	 Simultaneous	 pancreas	 kidney	
transplantation	 is	 the	 treatment	 of	 choice	 for	 most	 patients	
with	 type	 1	 diabetes	mellitus	 and	 ESKD	because	 it	 saves	 lives,	
improves	 the	 quality	 of	 life	 and	 is	 cost-effective	 [9].	 Recently,	
the	advent	of	antiretroviral	 therapy,	HIV	positive	patients	with	
concurrent	 ESKD	 are	 expected	 to	 have	 similar	 expected	 graft	
survival	 as	 non-HIV	 patients	 [10].	 However,	 the	 proposals	 to	
transplant	HIV	positive	patients	have	also	raised	several	ethical	
concerns.	Apart	 from	the	 interactions	between	antiviral	agents	
and	 immunosuppression,	 the	 increased	 risk	 of	 acute	 rejection	
observed	in	HIV	transplant	recipients	also	poses	major	challenges	
balancing	 the	 dose	 and	 types	 of	 immunosuppression	 use	 and	
a.	 All	patients	transplanted	for	type	1	diabetes	complicated	by	end	stage	renal	disease,	necessitating	haemodialysis
b.	 Immediately	post	transplantation/	when	ART	recommenced
c.	 The	patient	described	was	a	long-term	non	progressor	HIV	patient
d.	 Exact	follow	up	for	each	patient	not	specified,	however	between	2-5	years
UK:	United	Kingdom;	F:	Female;	M:	Male;	PVD:	Peripheral	Vascular	Disease;	NS:	Not	Specified;	HTN:	Hypertension;	IVDU:	Intravenous	Drug	Use;	
HCV:	Hepatitis	C	Virus;	IHD:	Ischaemic	Heart	Disease;	OP:	Osteoporosis;	Tx:	Transplantation;	HIV:	Human	Immunodeficiency	Virus;	VL:	Viral	Load;	
ART:	 Antiretroviral	 Therapy;	 RAL:	 Raltegravir;	 DRV:	 Darunavir;	 r:	 Ritonavir;	 ETV:	 Etravirine;	 d4T:	 Stavudine;	 3TC:	 Lamivudine;	 NFV:	 Nelfinavir;	
FTC:	Emtricitabine;	NVP:	Nevirapine;	ATV:	Atazanavir;	EFV:	Efavirenz;	TDF:	Tenofovir;	DTG:	Dolutegravir;	MVC:	Maraviroc;	T20:	Enfuviritide;	ZDV:	
Zidovudine;	ABC:	Abacavir;	FPV:	Fosamprenavir;	N/A:	Not	Applicable;	MI:	Myocardial	Infarction;	ATN:	Acute	Tubular	Necrosis;	CMV:	Cytomegalovirus;	
TB:	Tuberculosis;	HSV:	Herpes	Simplex	Virus;	AKI:	Acute	Kidney	Injury;	Y:	Yes;	N:	No;	F/U:	Follow	Up
Table 2	Characteristics	of	all	patients	undergoing	SPK	transplantation	in	the	setting	of	HIV	and	T1DM.
 Country Age/Sex Comorbidities
CD4  
at Tx 
HIV VL 
at Tx
ART  
pre Tx 
Days ART 
w/h post Tx
ART post 
Txb
Major 
complications
Survival
F/U
Patient Pancreas Kidney
Toso  
et al. [4]
Switzerland 39/F PVD 600 <50 Nil N/A Nil MI Y Y Y	 7 
	years
Genzini 
et al. [5]
Brazil 43/M NS 803 <50 NS NS NS ATN Y Y Y 5	
months
Miro  
et al. [1]
Spain 40/M HTN	 523 <39 Nil	for	6	
months
13 3TC,	TDF,	
RAL
Abscess,	
sepsis,	CMV
N N Y
9 
months
Akthar  
et al. [3] 
UK 50/M
HTN,	
hyperlipidemia
752 <50
RAL,	
DRV/r,	
ETV
Continued
RAL,	
DRV/r,	
ETV
Nil Y Y Y NS
Grossi  
et al. [2]
Italy 35/M NS 470 <50
d4T,	
3TC,	
NFV
25
ZDV,	3TC,	
EFV
Pancreatitis,	
haematoma,	
abscess
Y N Y NSd
 Italy 44/M Ex-IVDU,	HCV 470 80000 Nil 58 3TC,	ABC,	
FPV/r
TB,	bleeding,	
cholecystitis,	
abscess
Y Y Y	 NS
 Italy 31/F NS 698 <50
FTC,	
NVP,	
ATV/r
27
3TC,	ABC,	
ATV/r
Genital	HSV,	
AKI,	bleeding,	
abscess
Y Y Y NS
 Italy 49/M NS 598 <50
d4T,	
3TC,	
EFV	
41 3TC,	ABC,	
RAL
Acute	renal	
rejection,	
cholecystitis
Y Y Y NS
Hasan  
et al. 
(2017) 
(Current)
Australia 41/M
IHD,	seizures,	
OP
518 <20
TDF,	
DTG,	
MVC,	
T20
Continued	
TDF,	DTG,	
MVC,	T20
MI,	psoas	
abscess,	
splenic	infarct
Y Y Y
18 
months
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the	 inherent	 risk	 of	 opportunistic	 infections	 associated	 with	
immunosuppression	 such	 as	 T	 cell	 depleting	 agents	 for	 the	
management	of	acute	rejection.	
Nonetheless,	 this	 case	 supports	 that	 SPK	 transplantation	 is	
generally	safe,	with	 favourable	short-term	outcomes	 for	young	
patients	 with	 T1DM,	 renal	 failure	 and	 HIV,	 if	 a	 tailored	 and	
planned	program	is	used.	Future	studies	and	cases	should	expand	
on	 complex	 HIV	 patients	 with	 genotype	 mutations	 requiring	
transplantation.		
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